Science Corp, Merge Labs, and BrainCo have already turned 2026 into a notable year for BCI financing. The three rounds landed within a short span, giving the category unusual funding weight very early in the year. Unlike in the early years of Neuralink dominance, several firms are now raising at a scale that raises eyebrows. But to find out if the market is truly heating up, it is worth asking: how much has the field raised in the last 12 months?

To answer that, Neurofounders looked at a 17-company snapshot built around a narrow definition of brain-computer interface: technology that directly records neural signals and sends them into an external system that converts them into a meaningful control output. That excludes categories that are often grouped into BCI more loosely, including EEG-based state decoding, neuroanalytics, and non-closed-loop neuromodulation. 

The list also leaves out companies without enough public funding disclosure to support comparison. Valuation and market cap figures were included only where public or reasonably defensible estimates exist. The result is a narrower view of the field, but a more usable one. Within that 17-company snapshot, more capital flowed into BCIs over the last 12 months than in all prior years combined.

Over a Billion Raised in a Year

Across the 17 companies in this snapshot, disclosed funding over the last 12 months reached $1.75 billion. 13 of the 17 companies raised money in the last year. The total funding is a large number for a relatively narrow slice of the BCI market. At the same time, it should not be read as a total for the full category. It is a bounded snapshot built from companies with enough public funding visibility to compare. 

A small group of companies explains most of that total. Neuralink alone accounts for a $650 million Series E, followed by BrainCo with a $286.3 million strategic round, Merge Labs with a $252 million seed round, Science Corp with a $230 million Series C, and Synchron with a $200 million Series D. Together, those five represent the vast majority of capital raised in the period. Yet, they span different company profiles: long-established names, new entrants, clinical players, and firms positioned around broader consumer-clinical narratives. 

Below that top tier, the funding picture becomes thinner. Precision Neuroscience raised $41 million in a recent round whose series was not clearly disclosed in public reporting, while Phantom Neuro raised a $19 million Series A and NeuroBionics closed a $10 million seed round. Synaptrix Labs announced seed funding, but without disclosing the amount publicly (±$9 million) while INBRAIN’s latest capital came through a €4 million grant rather than a priced venture round. 

Subsense expanded its financing to $27 million through an additional $10 million top-up, but did not present it as a conventional named series. Cognixion’s latest $4.05 million financing is visible in private-company databases, though the round type is not cleanly public, and Paradromics’ recent financing is better captured in market databases than in a company-announced series label.

A separate group disclosed no new round at all in the same period, including Axoft, Blackrock Neurotech, CorTec, and NeuroXess. The market is still producing meaningful mid-sized financings, but the distance between the largest rounds and the rest of the field is widening. 

Taken together, the last 12 months were strong in absolute dollars, but not broad-based in distribution. The BCI market is starting to separate into funding tiers, with a handful of companies pulling further ahead while others remain technically credible but financially more toned down. 

Funding Doubles as Market Caps Soar

Before the last 12 months, the same 17 companies had already raised just under $1.6 billion. Over the past year, they raised even more: $1.75 billion. In other words, this snapshot saw more BCI funding in the last 12 months than in all prior years combined for the same set of firms. 

A number of the established names were already operating with substantial capital behind them before the latest rounds arrived. Neuralink had already raised $550 million, Science Corp $260 million, Synchron $145 million, Precision Neuroscience $142 million, Paradromics $111.22 million, and INBRAIN $95.32 million. Much of today’s financing is being layered onto companies that were already well capitalised, mostly to prepare for commercialization.

That earlier base now sits alongside a rapidly expanding valuation layer. Across the subset with public or defensible market cap data, combined capitalisation reaches $15.13 billion. Neuralink alone accounts for $9 billion of that figure, followed by Science Corp at $1.5 billion, BrainCo at $1.3 billion, Synchron at $1 billion, and Merge Labs at $850 million. 

Precision Neuroscience sits at $543 million, Paradromics at $500 million, and Blackrock Neurotech at $350 million, with Phantom Neuro and NeuroBionics further down the stack. Valuation visibility remains incomplete across the set, but even the disclosed estimates show how heavily value is concentrated around a relatively small number of firms.

A New Funding Stage

The capital stack is moving in a clear direction. Funding is rising, but it is not rising evenly. The leading BCI companies are pulling in large follow-on rounds on top of already substantial historical raises, while their valuation signals are shooting up. For that upper tier, cash is compounding; investor appetite appears to be strengthening around a small number of perceived category leaders.

The mix of companies in the snapshot points to a second shift. Newer entrants are arriving with far more capital than earlier cohorts typically did, with Merge Labs and Subsense standing out as examples, while BrainCo’s latest round sharply outweighs its previously disclosed funding base. 

At the same time, the long tail still matters. Firms like Axoft, CorTec, NeuroXess, Cognixion, and Synaptrix are operating on much smaller capital bases, yet still sit inside a serious technical market. The result is a more stratified BCI landscape: a handful of heavily financed leaders, a credible mid-tier, and a longer set of undercapitalised but still relevant players.

The snapshot: Axoft, Blackrock Neurotech, BrainCo, Cognixion, CorTec, INBRAIN Neuroelectronics, Merge Labs, Neuralink, NeuroBionics, NeuroXess, Paradromics, Phantom Neuro, Precision Neuroscience, Science Corp, Subsense, Synaptrix Labs, Synchron